Feedback / Questions
BRG01 - Biosyngen
https://www.prnewswire.com/news-releases/biosyngens-brg01-enters-phase-ii-clinical-trial-a-first-in-kind-autologous-ebv-specific-car-t-therapy-for-solid-tumors-on-recurrentmetastatic-nasopharyngeal-carcinoma-302197994.html
Jul 16, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next